Jump to Content

Professor Ross McKinnon 

Position: Visiting Academic Professor Ross McKinnon
Division/Portfolio: Division of Health Sciences
School/Unit: School of Pharmacy and Medical Sciences
Campus: City East Campus
Office: R5-27
Telephone: +61 8 830 22372
Fax: +61 8 830 21087
Email: Ross_dot_McKinnon_at_unisa_dot_edu_dot_au
URL for Business Card: http://people.unisa.edu.au/Ross.McKinnon


Welcome to my UniSA homepage. I am an Adjunct Professor of Pharmacy in the School of Pharmacy and Medical Sciences having spent 16 years with UniSA from 1995 to 2011.

SELECTED AWARDS, ACHIEVEMENTS AND APPOINTMENTS

2011: APSA Medal (Australasian Pharmaceutical Science Association)

2011: Millis Orator (AusBiotech)

2010-2011: Member, NHMRC Academy

2004: President, Australasian Pharmaceutical Science Association

2000: Australian Institute of Political Science Tall Poppy Award

1988: Flinders University Medal


Teaching interests

  • Pharmacotherapeutics

Professional associations

Australasian Pharmaceutical Science Association (APSA)

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)

Australian Society for Biochemistry and Molecular Biology (ASBMB)

International Society for the Study of Xenobiotics (ISSX)

AusBiotech

Australian Society for Medical Research

American Association of Pharmaceutical Scientists (AAPS)

Federation of International Pharmacists (FIP)


Qualifications

Bachelor of Pharmacy (SAIT) 1982

Bachelor of Science (Honours) (Flinders) 1988

Ph.D. (Flinders) 1993


Research interests

  • Pharmacogenetics / Pharmacogenomics
  • Molecular Pharmacology/Toxicology
  • UDP Glucuronosyltransferases
  • Cytochromes P450
  • Cancer Chemoprevention
  • Ethnopharmacology

Research publications

Humphreys KJ, McKinnon RA, Michael MZ. miR-18a targets CDC42 and plays a tumour suppressor role in colorectal cancer cells. PLOS One (Accepted October 2014)

Hu DH, Meech R, McKinnon RA, Mackenzie PI. Transcriptional regulation of human UDP-glucuronosyltransferase genes. Drug Metabolism Reviews (Accepted September, 2014)

Sorich MJ, Rowland A, McKinnon RA, Wiese M. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following PCI and in Asian populations treated with clopidogrel: A meta-analysis. Circulation: Cardiovascular Genetics Sep 25. 114.000669.

Dias MM, Pignon J-P, Baiget M, Karapetis C, Kweekel DM, Lara PM, Martinez-Balibrea E, McLeod HL, Páez D, Toffoli G, Wadelius M, McKinnon RA, Sorich MJ. The effect of the UGT1A1*28 allele on irinotecan-related survival: A collaborative systematic review and meta-analysis The Pharmacogenomics Journal 14(5):424-431 (2014)

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Annals of Oncology Aug 12. pii: mdu378. [Epub ahead of print]

Nandurkar H, Chong B, Salem H, Gallus A, Ferro V, McKinnon R. Low molecular weight heparin (LMWH) biosimilars: potential implications for clinical practice. Internal Medicine Journal 44(5):497-500 (2014)

Bruno A, Bates I, McKinnon R. Integrating science into pharmacy education: ideas for the future. Int Pharm J 32(1):56-58 (2014)

Simpson BS, Luo X, Costabile M, Caughey GE, Wang J, Claudie DJ, McKinnon RA, Semple SJ. Polyandric acid A, a clerodane diterpenoid from the Australian medicinal plant Dodonaea polyandra, attenuates pro-inflammatory cytokine secretion in vitro and in vivo. J Natural Products 77(1):85-91 (2014)

Dias MM, Ward HM, Sorich MJ, McKinnon RA. Exploration of the perceptions, barriers and drivers of pharmacogenomics practice among hospital pharmacists in Adelaide, South Australia. The Pharmacogenomics Journal 14(3):235-240 (2014)

Bruno A, Galbraith K, McKinnon R. Response to Global Supply of Health Professionals. Letter to the Editor. New England Journal of Medicine 370(23):2246-2248 (2014)

Guo D, Meech R, Lu L, McKinnon RA, Mackenzie PI. Polymorphisms and haplotypes of the UDP-Glucuronosyltransferase 2B7 gene promoter. Drug Metab Disp 42(5):854-862 (2014)

Simpson BS, Claudie DJ, Smith N, McKinnon RA, Semple SJ. Learning from both sides: experiences and opportunities in the investigation of Australian Aboriginal medicinal plants. J Pharm Pharmaceut Sci 16(2) 259 - 271 (2013)

Nandurkar H, Salem H, Gallus A, Chong B, Ferro V, McKinnon RA. Low molecular weight heparin (LMWH) biosimilars: potential implications for clinical practice. Internal Medicine Journal (in press)

Ozdemir V, LLerena A, McKinnon RA, Srivastava S, Dove ES, Ferguson LR, Maseelis M, Gurwitz D, Warnich L. CPPM 2013 onward: building a socio-technical GPS for global personalized medicine. Current Pharmacogenomics and Personalized Medicine 11(2):87-92 (2013)

Ngo SNT, Stupans I, McKinnon RA. Generic substitution in the treatment of epilepsy: patient attitudes and perceptions. Epilepsy and Behavior 26:64-66 (2013)

Cortis LJ, McKinnon RA, Anderson C. Palliative care is everyone’s business – including pharmacists. American Journal of Pharmaceutical Education 77(2): Article 21 (2013)

Ngo S, McKinnon RA. PPAR-alpha cloning, expression and characterisation. In Peroxisome proliferator-activated receptors (PPARS): Protocols and methods Humana Press. Series: Methods in Molecular Biology, Eds MZ Badr, JA Youssef. Vol. 952 pp7-34 (2013)

McKinnon RA, Ward MB, Sorich MJ. Pharmacogenomics in a global world series: A roadmap for Australia, prospects and challenges. Current Pharmacogenomics and Personalized Medicine 11(4): 1-3 (2013)

Anderson C, Plevin DM, McKinnon RA. Educating our students about pharmaceutical care for those living with cancer. American Journal of Pharmaceutical Education (Invited commentary) 76 (7) Article 119 (2012)

Simpson BS, Claudie DJ, Smith N, McKinnon RA, Semple SJ. Rare, seven-membered cyclic ether labdane diterpenoid from Dodonaea polyandra. Phytochemistry 84:141-146 (2012)

McKinnon RA, Hay S. Meeting the challenge in translating Australia’s medical research. Australian Quarterly 83(3):9-15 (2012)

Manasse H, Marriott JA, McKinnon RA (FIPEd Steering Committee). The future of pharmacy education – how are we creating it? Int Pharm J 28(1)12-14 (2012)

Sorich MJ, McKinnon RA. Personalized medicine: potential, barriers and contemporary issues. Current Drug Metabolism 13(7):1000-1006 (2012)

El Merhibi A, Ngo SNT, Marchant C, Crittenden TA, Stupans I, McKinnon RA. Cloning and characterization of a CYP3A subfamily member, CYP3A70, from Eastern grey kangaroo (Macropus giganteus). Gene 506(2):423-8 (2012)

Dias MM, McKinnon RA, Sorich MJ. The impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics 13(8):889-899 (2012)

Dias MM, Depala K, Ward H, Ward MB, Sorich MJ, Anderson C, McKinnon RA. Reforming pharmaceutical education to enhance the global uptake of personalised medicine. Current Pharmacogenomics and Personalized Medicine 10(3):231-238 (2012)

Callegari S, Gregory P, Sykes MJ, Bellon J, Andrews S, McKinnon RA, de Barros Lopes MA. Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity. PLOS Genetics 8(6): e1002755 (2012)

Anderson C, Ward HM, Corkindale D, Ward MB, Sorich MJ, McKinnon RA. Pharmacogenomics and personalized medicine: consumer perspectives, lessons learned in Australia and beyond. Current Pharmacogenomics and Personalized Medicine 10(2):170-177 (2012)

Anderson C, McKinnon RA. Educating pharmacists in the post-genomic era. American Journal of Pharmaceutical Education (Invited commentary) 75(6):Article 107 (2011)

El Merhibi A, Ngo SNT, Marchant C, Crittenden TA, Stupans I, McKinnon RA. Cytochrome P450 CYP3A in marsupials: Cloning and characterisation of the second identified CYP3A subfamily member, isoform 3A78 from koala (Phascolarctos cinereus). Comparative Biochemistry and Physiology 154(4):367-76 (2011)

Simpson BS, Claudie DJ, Smith N, Gerber JP, McKinnon RA, Semple SJ. Flavonoids from the leaves and stems of Dodonaea polyandra: a Northern Kaanju medicinal plant. Phytochemistry 72: 1883–1888 (2011)

McKinnon RA. Translating health discovery into clinical applications: an Australian perspective. Australasian Biotechnology 21(3): 13-14 (2011)

Callegari S, McKinnon RA, Andrews S, de Barros Lopes M. The MEF2 gene is essential for yeast longevity, with a dual role in cell respiration and maintenance of mitochondrial membrane potential. FEBS Letters 585: 1140-1146 (2011)

McKinnon RA. Getting to grips with burns. Pharmacy News. Published by Reed Business Information. September pp35-38 (2011)

Simpson BS, Claudie DJ, Gerber JP, Pyke SM, Wang J, McKinnon RA, Semple SJ. In vivo activity of benzoyl ester clerodane diterpenoid derivatives from Dodonaea polyandra. Journal of Natural Products 74 (4): 650–657 (2011)

Milic N, Ngo S, Height T, Marchant CL, McKinnon RA Pulmonary cytochrome P450 enzymes belonging to the CYP4B subfamily from an Australian marsupial, the tammar wallaby (Macropus eugenii) Comparative Biochemistry and Physiology C (Pharmacology Toxicology and Endocrinology) 153(1):60-66 (2011)

McKinnon RA. Psoriasis - More than skin deep. Pharmacy News. Published by Reed Business Information. December- January pp. 26-29 (2010)

McKinnon RA. Trends and treatments in HIV – when more is more. Pharmacy News. Published by Reed Business Information. October, pp36-40 (2010)

Sorich MJ, Vitry A, Ward MB, Horowitz J, McKinnon RA. Prasugrel versus clopidogrel for Cytochrome P450 2C19 genotyped subgroups: Integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis and Haemostasis 8(8):1678-1684 (2010)

Simpson B, Claudie D, Smith N, Wang J, McKinnon RA, Semple SJ. Evaluation of the anti-inflammatory properties of Dodonaea polyandra, a Kaanju traditional medicine. J Ethnopharmacol 132(1):340-343 (2010)

Plevin DP, Ward H, Ward MB, Sorich MJ, McKinnon RA. Targeted cancer therapies in Australia: clinical practice, pharmacy education and future directions. American Journal of Pharmaceutical Education 74(9): Article 169, 1-6 (2010)

Wang L, Angley MT, Sorich MJ, Young RL, McKinnon RA, Gerber JP. Is there a role for routinely screening children with autism spectrum disorder for creatine deficiency syndrome? Autism Research 3: 268-272 (2010)

Haddy CA, Ward H, Angley MT, McKinnon RA. Consumers’ views on pharmacogenetics – a qualitative study. Research in Social and Administrative Pharmacy 6:221-231 (2010)

Lewis B, Wigley PL, McKinnon RA. Chemoprevention of non-melanoma skin cancer, in Herbal Medicine: A cancer chemopreventive and therapeutic perspective (Editors: RK Sharma and Rajesh Arora), Jaypee Brothers Medical Publishers Pvt. Ltd, Delhi pp473-485 (Chapter 31) ISBN: 978-81-8448-841-8 (2010)

Ngo SNT, Stupans I, McKinnon RA. Correlation between peroxisome proliferation and up-regulation of cytochrome P450 CYP4A and peroxisomal beta-oxidation fatty acyl CoA oxidases (AOX) in the koala (Phascolarctos Cinereus). Gene Exp Genet Genom 3:1-6 (2010)

Callegari S, McKinnon RA, Andrews S, de Barros Lopes M. Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation. FEMS Yeast Research 10(2):188-194 (2010)

Wang L, Angley MT, McKinnon RA, Gerber JP, Abarno DV, Sorich MJ. Is urinary indolyl-3-acryloylglycine (IAG) a biomarker of autism with gastrointestinal symptoms? Biomarkers 14(8):596-603 (2009)

McKinnon RA, Lu CY. Assessing biosimilar medicines for clinical use. (Invited Editorial). Australian Prescriber 22(6)146-47 (2009)

McKinnon RA, Ward MB. Individualised medicine. In Australian Pharmaceutical Formulary, Sansom LN. Ed. 21st Edn, Pharmaceutical Society of Australia pp 33-36 (2009)

Mittal RR, McKinnon RA, Sorich MJ. Comparison of datasets for benchmarking QSAR methodologies in lead optimization. Journal of Chemical Information and Modeling 49(7):1810-1820 (2009)

Kong S, Ngo, S, McKinnon RA, Stupans I. Cloning and expression of the koala (Phascolarctos Cinerus) liver cytochrome P450 reductase. Comparative Biochemistry and Physiology C (Pharmacology Toxicology and Endocrinology) 150:1-9 (2009)

Ward MB, Sorich MJ, Evans AM, McKinnon RA. Cytochrome P450 3: Clinically relevant drug interactions. Journal of Pharmacy Practice and Research 39(1):55-58 (2009)

Leong EM, Semple SJ, Angley MT, Siebert W, Petkov J, McKinnon RA. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why? Complementary Therapies in Medicine 17:216-223 (2009)

Mittal RR, Harris L, McKinnon RA, Sorich MJ. Partial charge calculation method affects CoMFA QSAR prediction accuracy. Journal of Chemical Information and Modeling 49(3):704-9 (2009)

Moridani M, Maitland-Van Der Zee, A, Sasaki H, McKinnon R, Fleckstein L, Shah V. Pharmacogenetics in individualized medicine: methods, regulatory and clinical applications. AAPS Journal 11(2):214-6 (2009)

Mittal RR, McKinnon RA, Sorich MJ. The effect of molecular fields, lattice spacing and analysis options on CoMFA predictive ability. QSAR and Combinatorial Science 28(6-7):637-644 (2009)

Ward MB, Sorich MJ, McKinnon RA. Cytochrome P450 2: Genetics of inter-individual variability. Journal of Pharmacy Practice and Research 38:3:226-229 (2008)

Beetstra S, Suthers G, Dhillon V, Salisbury C, Turner J, Altree M, McKinnon R, Fenech M. Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer. Cancer Epidemiol Biomarkers Prev. 17(10):2565-71 (2008)

McKinnon RA, Ward MB, Sorich MJ. Cytochrome P450 1: Multiplicity and function. Journal of Pharmacy Practice and Research 38(1):55-57 (2008)

Jones BR, El-Merhibi A, Ngo SN, Stupans I, McKinnon RA. Hepatic cytochrome P450 enzymes belonging to the CYP2C subfamily from an Australian marsupial, the koala (Phascolarctos cinereus). Comp Biochem Physiol C Toxicol Pharmacol. 148(3):230-7 (2008)

El-Merhibi A, Ngo SNT, Jones BR, Milic NL, Stupans I, McKinnon RA. Molecular insights into xenobiotic disposition in Australian marsupials. Aust J Ecotox 13:7-18 (2008)

Mittal R, McKinnon RA, Sorich MJ. Effect of steric molecular field settings on CoMFA predictivity J Mol Mod 14(1):59-67 (2008)

Ward M, Sorich MJ, McKinnon RA. Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics. 9(8):1027-33 (2008)

Sykes M, McKinnon RA, Miners JO. Alignment and docking studies of seventy CYP2C9 substrates using the shape and chemistry of flurbiprofen as a template. J Med Chem 51(4):780-791 (2008)

Sorich MJ, Smith PA, Miners JO, McKinnon RA. Recent advances in UDP glucuronosyltransferase substrate in silico modelling. Curr Drug Metab 9:60-69 (2008)

McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the implementation of pharmacogenomics into clinical practice. Therapeutics and Clinical Risk Management 3(5):751-759 (2007)

Ngo S, McKinnon RA, Stupans I. Hepatic nuclear receptor PPAR-alpha in the koala (Phascolarctos cinereus): cloning and molecular characterization. Comparative Biochemistry and Physiology C (Pharmacology Toxicology and Endocrinology) 146:375-382 (2007)

Chui S, Onishko C, Turner S, Coulthard KP, McKinnon RA. Retrospective case note review of the incidence of vancomycin-induced red man syndrome. J Pharmacy Practice and Research 37(2):124-127 (2007)

Corkindale D, Ward H, McKinnon R. Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia. Personalized Medicine 4(2):191-199 (2007)

Angley M, Semple S, Ellis D, Paterson F, Hewton C, Chan W, Young R, McKinnon R. Children and autism 2: management with complementary medicines and dietary interventions. Australian Family Physician 36(10):827-830 (2007)

Angley M, Semple S, Ellis D, Chan W, Young R, McKinnon R. Children and autism 1: recognition and pharmacological management. Australian Family Physician 36(9):741-744 (2007)

Tran TT, Heng SS, Abarno D, McKinnon RA, Ngo S. Molecular mechanism of drug interactions involving complementary medicines: the role of cytochrome P450 CYP3A. Integrative Medicine Insights 2:73-81 (2007) [open access journal]

Dias MM, Mittal R; McKinnon RA; Sorich MJ. Systematic statistical comparison of CoMSIA molecular fields for computer-aided lead optimization. Journal of Computer Information and Modeling 46:2015-2021 (2006)

Sorich MJ, Miners JO, McKinnon RA, Smith PA. The importance of local structure in predicting chemical metabolism by UDP glucuronosyltransferases. Journal of Computer Information and Modeling 46:2692-2697 (2006)

Ngo S, McKinnon RA, Stupans I. Cloning and expression of koala liver CYP4A (Phascolarctos cinereus) Gene 376(1):123-132 (2006)

Toy A, Anderson B, McKinnon RA, Gilbert AL. Assessment of a possible role for clinical pharmacists in identifying pharmacogenomic interventions. Journal of Pharmacy Practice and Research 36(1):35-39 (2006)

Zi Y, Tait P, Young R, McKinnon R, Angley M. Immunisation and autism: sifting myth from reality. Australian Pharmacist 25(7):554-558 (2006)

Beetstra S, Salisbury C, Turner J, Altree M, McKinnon R, Suthers G, Fenech M. The impact of folic acid deficiency on chromosome damage in BRCA1 and BRCA2 germline mutation carriers with and without breast cancer. Carcinogenesis 27(3):517-24 (2006)

Angley M, McKinnon R, Young R, Evans A. Children and autism: can the pharmacist help? Australian Pharmacist 25(6):468-472 (2006)

Mackenzie PI, Gregory PA, Lewinsky RH, Yasmin N, Height T, McKinnon RA, Gardner-Stephen DA. Polymorphic variations in the expression of chemical detoxifying UDP glucuronosyltransferases. Tox Appl Pharm 207(Suppl):77-83 (2005)

Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. In vitro and in silico approaches for prediction of drug metabolism parameters for drugs eliminated by glucuronidation. Ann Rev Pharmacol Toxicol 44:1-25 (2004)

Boye SL, Kerdpin O, Elliot DJ, Miners JO, Kelly L, McKinnon RA, Bhasker CR, Yoovathaworn K, Birkett DJ. Optimising bacterial expression of catalytically active human cytochromes P450: Comparison of CYP2C8 and CYP2C9. Xenobiotica 34: 49-60 (2004).

Sorich MJ, McKinnon RA, Miners JO, Winkler DA, Smith PA. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. J Med Chem 47(21):5311-7 (2004)

Buckley P, McKinnon RA. Pharmacogenomics, ethics and the community. Australian Pharmacist 23(1):22-24 (2004)

Sorich MJ, McKinnon RA, Miners JO, Smith PA. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol 65(2):301-308 (2004)

Smith PA, Sorich MJ, Low LSC, McKinnon RA, Miners JO. Towards integrative ADME prediction: past, present and future trends in modelling metabolism by UDP glucuronosyltransferases. Journal of Molecular Graphics and Modeling 22:507-517 (2004)

Ngo S, McKinnon RA, Stupans I. Induction of Microsomal Cytochrome P450 CYP4A, Peroxisomal Acyl CoA Oxidase (AOX) and Peroxisome Proliferator Activated Receptor Alpha (PPARalpha) in the Common Brushtail Possum Liver, Trichosaurus vulpecula, by Eucalyptus Terpenes. Comparative Biochemistry and Physiology 136(2):165-173 (2003)

Smith PA, Sorich MJ, McKinnon RA, Miners JO. In silico insights: chemical and structural characteristics associated with UDP-glucuronosyltransferase (UGT) substrate selectivity. Clin Exp Physiol Pharmacol 30(11):836-840 (2003)

McKinnon RA, Buckley P. Pharmacogenomics: Snips, chips and the future of drug therapy. Australian Pharmacist 22(11):852-853 (November) 2003

Sorich MJ, McKinnon RA, Winkler DA, Burden FR, Miners JO, Smith PA. Comparison of linear and non-linear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms. J Chem Inf Comput Sci 43(6):2019-2024 (2003)

McKinnon RA, Ward MB. Genomics and proteomics series: part 2. The emergence of pharmacogenomics. J Pharm Pract Res 2003 (June); 33: 133-7.

Smith PA, McKinnon RA, Sorich MJ, Miners JO. Pharmacophore and quantitative structure activity relationship (QSAR) modelling: Complementary approaches to the rationalisation and prediction of UDP glucuronosyltransferase 1A4 (UGT1A4) substrate selectivity. Journal of Medicinal Chemistry 46(9):1617-26 (2003).

Ngo S, McKinnon RA, Stupans I. Identification and cloning of two forms of koala liver peroxisomal fatty Acyl CoA Oxidase from the koala (Phascolarctos Cinereus). Gene 309(2):91-99 (2003)

Miners JO, Mackenzie PI, McKinnon RA. Clinical significance of polymorphisms in UDP human glucuronosyltransferase genes Toxicology 181-182:453-6 (2002)

Sorich MJ, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modeling of UDP-Glucuronosyltransferase 1A1 (UGT1A1) Substrates. Pharmacogenetics 12:635-646 (2002)

Evans A, McKinnon R. Prediction and interpretation of potential drug interactions. in Australian Pharmaceutical Formulary, Sansom LN. Ed. 18th Edn, Pharmaceutical Society of Australia, Canberra (2002) pp256-266

Kong S, McKinnon RA, Mojarrabi B, Stupans I. Absence of type 1 11b-hydroxysteroid dehydrogenase enzyme in koala (Phascolarctos cinereus) liver. Comp Biochem Physiol C Toxicol Pharmacol. 131(1):39-50 (2002)

Stupans I, Jones B, McKinnon RA. Xenobiotic metabolism in marsupials. Comparative Biochemistry and Physiology, 128 (3):367-76 (2001)

McKinnon RA, Evans AM. Cytochrome P450: Clinically relevant drug interactions. Aust J. Hosp Pharm. 30(4):146-149 (2000)

Liapis P, Pass GJ, McKinnon RA, Stupans I. Characterisation of tolbutamide hydroxylase activity in the common brushtail possum, (Trichosurus vulpecula) and koala (Phascolarctos cinereus): inhibition by the Eucalyptus terpene 1,8-cineole. Comparative Biochemistry and Physiology 127:351-357 (2000)

Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyl-transferase genes: Functional consequences and clinical relevance. Clin Chem Lab Med. 38(9):889-92 (2000)

Ngo S, Kong S, , Kirlich A, McKinnon RA, Stupans I. Cytochrome P450 4A, peroxisomal enzymes and nicotinamide co-factors in koala liver. Comparative Biochemistry and Physiology 127:327-334 (2000)

McKinnon RA, Evans AM. Cytochrome P450: Pharmacogenetics Aust J. Hosp Pharm. 30:102-105 (2000)

McKinnon RA. Cytochrome P450: Multiplicity and function. Aust J. Hosp Pharm. 30:54-57(2000)

Miners JO, McKinnon RA. CYP1A in Metabolic Drug Interactions. Lippincott Williams & Wilkins, Philadelphia, PA pp 61 - 74 (2000)

Dalton TP, Miller ML, Wu X, Menon A, Ciancolo E, McKinnon RA, Smith PW, Robinson LJ, Nebert DW. Refining the mouse chromosomal location of Cdn, the major gene associated with susceptibility to cadmium-induced testicular necrosis. Pharmacogenetics 10:141-151 (2000)

Stupans I, Kong S, Kirlich A, McKinnon RA ,Murray M. Testosterone dehydrogenase activity in koala liver: characterisation of co-factor and steroid substrate differences. Comparative Biochemistry Physiology 125:245-250 (2000)

Evans AM, McKinnon RA. Clinically important drug interactions. in Australian Pharmaceutical Formulary, Sansom LN. Ed. 17th Edn, Pharmaceutical Society of Australia, Canberra pp272-279 (2000)

Stupans I, Kong S, Kirlich A, Murray M, Bailey E, Jones BR, McKinnon RA. Hepatic microsomal enzyme activity in the koala and tammar wallaby: high 17b-hydroxysteroid oxidoreductase activity in koala liver microsomes. Compar. Biochem. Physiol. 123:67-73 (1999)

McKinnon RA, Nebert DW. Cytochrome P450 knockout mice: new toxicological models. Clin Exp Pharmacol Physiol 25:783-788 (1998)

Genter MB. Liang HC, Gu J, Ding XX, Negishi M, McKinnon RA. Nebert DW. Role of Cyp2a1 and 2g1 in acetaminophen metabolism and toxicity in the olfactory mucosa of the Cyp1a2 (-/-) mouse. Biochem Pharmacol 55(11):1819-1826 (1998)

Stupans I, Kirlich A, McKinnon RA. Thiopurine Methyltransferase: No evidence of activation by its substrates. Life Sci. 62:343-350 (1998)

McKinnon RA, Nebert DW. Environmental Mutagenesis: In Environmental and Occupational Medicine. 3rd Edn. W. Rom Ed. Lippincott-Raven, New York 187-195 (1998)

Liang HC, McKinnon RA, Nebert DW. Sensitivity of CYP1A1 mRNA inducibility by dioxin is the same for Cyp1a2(+/+) wild-type and Cyp1a2 (-/-) null mutant mice. Biochem Pharmacol 54(10):1127-1131 (1997)

Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME. The role of xenobiotic metabolising enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 367:153-160 (1997)

Puga A, Nebert DW, McKinnon RA, Menon AG. Genetic polymorphisms in human drug-metabolising enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit Rev in Toxicol 27:199-222 (1997).

McKinnon RA, Wiese M. Factors influencing Drug Metabolism. in Australian Pharmaceutical Formlary, Sansom LN. Ed. 16th Edn, pp125-130, Pharmaceutical Society of Australia, Canberra (1997)

Nebert DW, McKinnon RA. General principles of toxicity: Genetic determinants of toxic risk. In ILO Encyclopedia of Toxicology, Volume 2, Editor: E. Silbergeld, pp 33.19 - 33.26, (1998).

McKinnon RA, McManus ME.. Localization of cytochromes P450 in human tissues: implications for chemical carcinogenesis. Pathology 28:148-155 (1996).

Nebert, DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280 (1996)

Liang H-C, Li H, McKinnon RA, Potter SS, Duffy JJ, Puga A, Nebert DW. Cyp1a2 (-/-) mice develop normally but display abnormal drug metabolism. Proc Natl Acad Sci USA. 93:1671-1676 (1996)

McKinnon RA, McManus ME. Function and localization of cytochromes P450 involved in the metabolic activation of food-derived heterocyclic amines. Proceedings of the 23rd International Symposium of the Princess Takamatsu Cancer Research Fund. 23:143-153, (1995)

McKinnon RA, Burgess WM, Hall P de la M, Gonzalez FJ, Roberts-Thomson SJ, McManus ME. Characterization of CYP3A gene subfamily expression in human gastrointestinal tissues.Gut 36:259-267 (1995)

McKinnon RA, Nebert DW. Possible role of cytochrome P450 in systemic lupus erythematosis. Lupus 3:473-478 (1994)

McKinnon RA, Burgess WM, Gonzalez FJ, Gasser R, McManus ME. Species-specific expression of CYP4B1 in rabbit and human gastrointestinal tissues. Pharmacogenetics 4:260-270 (1994)

Nebert DW , McKinnon RA. Cytochrome P450: Evolution and functional variability. In Progress in Liver Diseases, Volume 14, pp 1-31, (1994

McKinnon RA, Burgess WM, Gonzalez FJ, McManus ME. Metabolic differences in colon mucosal cells. Mutat Res 290:27-33 (1993)

McKinnon RA, Burgess WM, Hall P de la M, Abdul-Aziz Z, McManus ME. Metabolism of food-derived heterocyclic amines in human and rabbit tissues by P4503A proteins in the presence of flavonoids. Cancer Res 52:2108s-2113s (1992)

McKinnon RA, Hall P de la M, Quattrochi LC, Tukey RH, McManus ME. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 14: 848-856 (1991)

McManus ME and McKinnon RA. Measurement of cytochrome P450 activation of xenobiotics using the Ames/Salmonella test. In Methods in Enzymology:Cytochrome P450 Vol 206. EF Johnson, MR Waterman Eds. pp501-509 (1991).

Burnet RB, Radden HS, Easterbrook EG, McKinnon RA. Treatment of premenstrual syndrome with spironolactone. Aust. NZ J. Obstet. Gynaecol. 31:366-368 (1991)


Expertise for Media Contact

I am able to provide media comment in the following areas of expertise:

Discipline: Pharmacy

  • Pharmaceutical Biotechnology
  • Pharmacogenetics
  • Pharmacogenomics

Community Service

Organisation Name:   Therapeutic Goods Administration
Section:   Pharmaceutical SubComittee
Type of Organisation:   Government Board or committee
Level of involvement:   Member

Organisation Name:   AIPS SA Tall Poppy Campaign
Type of Organisation:   Community organisation
Organisation URL:   http://www.aips.net.au/tallpoppies/
Level of involvement:   Chair
Year from:   2007
Year to:   2009


Research Degree Supervisor

I am involved in two primary areas of research, the genetic basis of variability in response to drugs and skin cancer chemoprevention.

Current Projects:

Molecular Determinants of Drug and Chemical Metabolism
 Originally funded by an NHMRC Program grant, this project brings together expertise in drug and chemical metabolism from Flinders Medical Centre and the College of Pharmacy at the University of South Australia. The project has three broad areas: structure-function studies relating to drug metabolising enzymes such as the cytochromes P450 and UDP glucuronosyltransferases, the physiological and toxicological significance of these enzymes and individual and population variability in drug metabolism.
Skin Cancer Chemoprevention
 Cancer chemoprevention is the use of specific agents to reverse, suppress or prevent cancer. The promise of chemoprevention is that it might be used to reduce the incidence of cancer in those who are most likely to develop the disease (e.g. skin cancer in people who have been exposed to large levels of sunlight).We have recently demonstrated that anti-arthritic medications have impressive skin cancer chemopreventive actions in several experimental models. We are now focused on establishing the precise molecular basis of these effects and on establishing efficacy in human trials. Project in collaboration with Prof Allan Evans.




Change | Staff home page help